The filing is a regulatory progress update with no immediate revenue implications. Traders should monitor for study results and FDA submission status in late 2026, but near-term stock movement is unlikely from this announcement alone.
Price Chart
Executive Summary
Intelligent Bio Solutions announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. clearance of its fingerprint drug screening system for codeine. The study will enroll 135 donor participants and 9 operator participants, with data collection expected to complete by end of July 2026. This is a routine clinical milestone with no financial data provided.
Key Facts
- Multi-site Method Comparison Study initiated for FDA 510(k) submission for codeine assay
- 135 donor participants and 9 operator participants to be enrolled
- Study partnered with CenExel Clinical Research
- Enrollment and data collection expected by end of July 2026
- No financial figures or guidance provided in the filing
Financial Impact
No financial impact disclosed; pre-revenue development-stage company
Risk Factors
- Study results may not support FDA clearance
- Regulatory approval timeline uncertain
- Company has minimal revenue and depends on capital markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026780 |
| Exhibit: ex99-1.htm | 0001493152-26-026780 |
| Document: 0001493152-26-026780-index-headers.html | 0001493152-26-026780 |
| Document: 0001493152-26-026780-index.html | 0001493152-26-026780 |
| Document: 0001493152-26-026780.txt | 0001493152-26-026780 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 10-K/A | $1.69 | awaiting T+20 | — | $1.64 (−2.67%) |
Oct 13, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $1.64 (+13.10%) |
Sep 24, 2026 4w ago | EFFECT | $1.71 $1.69 | ▲ +1.46% | ▲ +1.04% | $1.64 (+4.09%) |
Sep 15, 2026 5w ago | S-3 | $1.97 $1.48 | ▼ −24.87% | ▼ −28.05% | $1.64 (−16.75%) |
Sep 11, 2026 6w ago | 8-K | $2.07 $1.51 | ▼ −27.05% | ▼ −29.32% | $1.64 (−20.77%) |
Sep 9, 2026 6w ago | 8-K | $2.24 $1.59 | ▼ −29.02% | ▼ −30.96% | $1.64 (−26.79%) |
Sep 2, 2026 7w ago | 8-K | $2.30 $1.66 | ▲ +27.83% | ▲ +26.64% | $1.64 (+28.70%) |
Aug 19, 2026 9w ago | 8-K | $2.67 $2.05 | ▼ −23.22% | ▼ −21.70% | $1.64 (−38.58%) |
Aug 19, 2026 9w ago | Press Release | $2.67 $2.05 | ▲ +23.22% | ▲ +21.70% | $1.64 (+38.58%) |
Aug 17, 2026 10w ago | Press Release | $3.37 $2.05 | ▼ −39.17% | ▼ −37.19% | $1.64 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers